Current status of antibody therapy for breast cancer
- 1 January 2004
- journal article
- review article
- Published by Springer Nature in Breast Cancer
- Vol. 11 (1) , 10-14
- https://doi.org/10.1007/bf02967994
Abstract
Antibody therapy with trastuzumab has greatly impacted breast cancer treatment. Combination treatment with trastuzumab is regarded currently as a first-line therapy for metastatic breast cancers that overexpress Her-2. It has become routine practice to examine the status of Her-2 expression in primary tumors. The impact of this therapy might be as great as that of endocrine therapy from a historical point of view. A number of new approaches using trastuzumab for seeking individualized treatment are being tested in current clinical trials. We reviewed recent advances in trastuzumab treatment and discuss the future of antibody therapy for breast cancer.Keywords
This publication has 20 references indexed in Scilit:
- HER-2 Analysis in Tissue Microarrays of Archival Human Breast CancerApplied Immunohistochemistry & Molecular Morphology, 2003
- Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER‐2 in 426 breast carcinomas from 37 centresThe Journal of Pathology, 2003
- Preoperative Therapy With Trastuzumab and Paclitaxel Followed by Sequential Adjuvant Doxorubicin/Cyclophosphamide for HER2 Overexpressing Stage II or III Breast Cancer: A Pilot StudyJournal of Clinical Oncology, 2003
- Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growthAnnals of Oncology, 2002
- Preoperative/neoadjuvant medical therapy for early breast cancerThe Lancet Oncology, 2001
- Docetaxel and Herceptin: Foundation for Future StrategiesThe Oncologist, 2001
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancersOncogene, 1999
- c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast CancerNew England Journal of Medicine, 1994
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987